These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 12736475)

  • 1. Role of fibrillation cycle length in spontaneous and drug-induced termination of human atrial fibrillation.
    Fujiki A; Sakabe M; Nishida K; Mizumaki K; Inoue H
    Circ J; 2003 May; 67(5):391-5. PubMed ID: 12736475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spectral characteristics of human atrial fibrillation waves of the right atrial free wall with respect to the duration of atrial fibrillation and effect of class I antiarrhythmic drugs.
    Fujiki A; Nagasawa H; Sakabe M; Sakurai K; Nishida K; Mizumaki K; Inoue H
    Jpn Circ J; 2001 Dec; 65(12):1047-51. PubMed ID: 11767996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-induced changes in fibrillation cycle length and organization index can predict chemical cardioversion of long-lasting atrial fibrillation with bepridil alone or in combination with aprindine.
    Fujiki A; Sakabe M; Nishida K; Sugao M; Tsuneda T; Iwamoto J; Mizumaki K; Inoue H
    Circ J; 2004 Dec; 68(12):1139-45. PubMed ID: 15564697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation: electrophysiological determinants of enhanced conversion efficacy.
    Stambler BS; Wood MA; Ellenbogen KA
    Circulation; 1997 Dec; 96(12):4298-306. PubMed ID: 9416896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up of changes in fibrillation waves in patients with persistent atrial fibrillation: spectral analysis of surface ECG.
    Sasaki T; Niwano S; Sasaki S; Imaki R; Yuge M; Hirasawa S; Satoh D; Moriguchi M; Fujiki A; Izumi T
    Circ J; 2006 Feb; 70(2):169-73. PubMed ID: 16434810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting the efficacy of antiarrhythmic agents for interrupting persistent atrial fibrillation according to spectral analysis of the fibrillation waves on the surface ECG.
    Niwano S; Sasaki T; Kurokawa S; Kiryu M; Fukaya H; Hatakeyama Y; Niwano H; Fujiki A; Izumi T
    Circ J; 2009 Jul; 73(7):1210-8. PubMed ID: 19436116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-invasive assessment of fibrillatory activity in patients with paroxysmal and persistent atrial fibrillation using the Holter ECG.
    Bollmann A; Sonne K; Esperer HD; Toepffer I; Langberg JJ; Klein HU
    Cardiovasc Res; 1999 Oct; 44(1):60-6. PubMed ID: 10615390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylactic statin administration may prevent shortening of the fibrillation cycle length in patients with new-onset atrial fibrillation.
    Oikawa J; Niwano S; Niwano H; Ishizue N; Yoshizawa T; Satoh A; Kurokawa S; Hatakeyama Y; Fukaya H
    Int Heart J; 2013; 54(6):371-6. PubMed ID: 24309446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Electrocardiographic and electrophysiological characteristics of atrial fibrillation organized into atrial flutter by oral administration of class I antiarrhythmic agents.
    Ohmura K; Kobayashi Y; Miyauchi Y; Endoh Y; Atarashi H; Katoh T; Takano T
    Pacing Clin Electrophysiol; 2003 Mar; 26(3):692-702. PubMed ID: 12698669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Observations from intraatrial recordings on the termination of electrically induced atrial fibrillation in humans.
    Sih HJ; Ropella KM; Swiryn S; Gerstenfeld EP; Sahakian AV
    Pacing Clin Electrophysiol; 1994 Jul; 17(7):1231-42. PubMed ID: 7937229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of verapamil and procainamide on atrial fibrillation-induced electrical remodeling in humans.
    Daoud EG; Knight BP; Weiss R; Bahu M; Paladino W; Goyal R; Man KC; Strickberger SA; Morady F
    Circulation; 1997 Sep; 96(5):1542-50. PubMed ID: 9315545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abrupt changes in fibrillatory wave characteristics at the termination of paroxysmal atrial fibrillation in humans.
    Petrutiu S; Sahakian AV; Swiryn S
    Europace; 2007 Jul; 9(7):466-70. PubMed ID: 17540663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repetitive evaluation of fibrillation cycle length predicts the efficacy of bepridil for interruption of long-lasting persistent atrial fibrillation.
    Aoyama Y; Niwano S; Niwano H; Satoh A; Kishihara J; Ishikawa S; Murakami M; Fukumoto K; Ueno K; Izumi T
    Int Heart J; 2011; 52(6):353-8. PubMed ID: 22188708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maintenance of sinus rhythm and recovery of atrial mechanical function after cardioversion with bepridil or in combination with aprindine in long-lasting persistent atrial fibrillation.
    Fujiki A; Tsuneda T; Sakabe M; Nakagawa K; Mizumaki K; Hirai T; Inoue H
    Circ J; 2004 Sep; 68(9):834-9. PubMed ID: 15329504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electrophysiological effects of flecainide and propafenone on atrial fibrillation cycle and relation with arrhythmia termination.
    Biffi M; Boriani G; Bronzetti G; Capucci A; Branzi A; Magnani B
    Heart; 1999 Aug; 82(2):176-82. PubMed ID: 10409531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological cardioversion of persistent atrial fibrillation with and without a history of drug-resistant paroxysmal atrial fibrillation.
    Fujiki A; Sakamoto T; Iwamoto J; Nishida K; Nagasawa H; Mizumaki K; Inoue H
    Circ J; 2006 Sep; 70(9):1138-41. PubMed ID: 16936425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Electrophysiologic effects and efficacy of cibenzoline on stimulation-induced atrial fibrillation and flutter and implications for treatment of paroxysmal atrial fibrillation.
    Kühlkamp V; Meerhof J; Schmidt F; Mayer F; Ickrath O; Haasis R; Seipel L
    Am J Cardiol; 1990 Mar; 65(9):628-32. PubMed ID: 2309633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Scoring System for Distinction Between Paroxysmal and Non-Paroxysmal Atrial Fibrillation.
    Oikawa J; Niwano S; Fukaya H; Nakamura H; Igarashi T; Fujiishi T; Ishizue N; Yoshizawa T; Satoh A; Kishihara J; Murakami M; Ako J
    Circ J; 2017 May; 81(6):788-793. PubMed ID: 28250286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacologic management of atrial fibrillation: current therapeutic strategies.
    Lévy S
    Am Heart J; 2001 Feb; 141(2 Suppl):S15-21. PubMed ID: 11174354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined transesophageal left atrial pacing and antiarrhythmic therapy in the treatment of atrial flutter.
    Matiouchine GV; Shulman VA; Balog AI; Bezruk AP; Golovenkin SE
    Pacing Clin Electrophysiol; 1996 Nov; 19(11 Pt 2):1947-50. PubMed ID: 8945075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.